Slayback Pharma LLC

Azurity Pharmaceuticals, Inc.

Mahadeo Vasant Mahadik

Ashish Anilrao Dubewar

Rahul Dhulaji Bhise

Ajay Kumar Singh

Molugu Prashanth Reddy

Sumitra Ashokkumar Pillai

Praveen Kumar Subbappa

Shanker Mamidi

Mayur Anshiram Adhav

Raghavender Rao Kategher

Nagaraj Gangam

Stable, ready-to-use injectable pharmaceutical compositions are provided, comprising the combination of neostigmine, glycopyrrolate, and a pharmaceutically acceptable liquid vehicle, optionally with additional pharmaceutically acceptable excipients. Other aspects of the invention relate to methods for making such compositions and methods of using such compositions for reversing the effects of non-depolarizing neuromuscular blocking agents. Preferably, the composition comprises neostigmine methylsulfate, glycopyrronium bromide, and a pharmaceutically acceptable liquid vehicle, and is provided in a pre-filled, ready-to-use sealed container, such as a pre-filled syringe, suitable for intravenous administration.

Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate

The present invention relates to stable liquid composition suitable for parenteral administration in the form of a solution comprising:

Stable liquid compositions of netupitant and palonosetron

The present invention relates to stable liquid compositions suitable for parenteral administration in the form of a solution comprising: The compositions are suitable for subcutaneous, intravenous, or intramuscular administration. The invention further relates to methods for manufacturing the compositions and methods of using such compositions for prevention, treatment or management of nausea and vomiting.

The present invention provides stable, ready-to-use injectable pharmaceutical compositions, comprising the combination of neostigmine, glycopyrrolate, a stabilizing amount of one or more aminopolycarboxylic acids, and a pharmaceutically acceptable liquid vehicle. Other aspects of the invention relate to methods for making such compositions and methods of using such compositions for reversing the effects of non-depolarizing neuromuscular blocking agents. Preferably, the composition comprises neostigmine methylsulfate, glycopyrronium bromide, ethylenediaminetetraacetic acid (EDTA) and a pharmaceutically acceptable liquid vehicle, and is provided in a pre-filled, ready-to-use sealed container, such as a pre-filled syringe, suitable for intravenous administration.

Growing community of inventors

Hyderabad Telangana, India

Mahadeo Vasant Mahadik